vs

Side-by-side financial comparison of Apollo Commercial Real Estate Finance, Inc. (ARI) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Apollo Commercial Real Estate Finance, Inc. is the larger business by last-quarter revenue ($73.3M vs $37.2M, roughly 2.0× Organogenesis Holdings Inc.). On growth, Apollo Commercial Real Estate Finance, Inc. posted the faster year-over-year revenue change (4.0% vs -57.1%). Over the past eight quarters, Apollo Commercial Real Estate Finance, Inc.'s revenue compounded faster (-4.6% CAGR vs -46.5%).

Apollo Commercial Real Estate Finance, Inc. is a real estate investment trust that originates, acquires and manages commercial real estate debt assets including mortgages, mezzanine loans and mortgage-backed securities, primarily operating in the U.S. market to deliver consistent risk-adjusted returns.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

ARI vs ORGO — Head-to-Head

Bigger by revenue
ARI
ARI
2.0× larger
ARI
$73.3M
$37.2M
ORGO
Growing faster (revenue YoY)
ARI
ARI
+61.0% gap
ARI
4.0%
-57.1%
ORGO
Faster 2-yr revenue CAGR
ARI
ARI
Annualised
ARI
-4.6%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ARI
ARI
ORGO
ORGO
Revenue
$73.3M
$37.2M
Net Profit
$29.2M
Gross Margin
30.8%
Operating Margin
39.7%
-185.1%
Net Margin
39.9%
Revenue YoY
4.0%
-57.1%
Net Profit YoY
-28.2%
EPS (diluted)
$0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARI
ARI
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$73.3M
$225.6M
Q3 25
$61.6M
$150.9M
Q2 25
$70.9M
$101.0M
Q1 25
$65.8M
$86.7M
Q4 24
$70.5M
$126.7M
Q3 24
$71.6M
$115.2M
Q2 24
$81.1M
$130.2M
Net Profit
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
$29.2M
$43.7M
Q3 25
$50.8M
$21.6M
Q2 25
$20.7M
$-9.4M
Q1 25
$26.0M
$-18.8M
Q4 24
$40.7M
$7.7M
Q3 24
$-91.5M
$12.3M
Q2 24
$35.8M
$-17.0M
Gross Margin
ARI
ARI
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
ARI
ARI
ORGO
ORGO
Q1 26
-185.1%
Q4 25
39.7%
28.1%
Q3 25
82.8%
13.7%
Q2 25
29.4%
-12.5%
Q1 25
39.7%
-30.9%
Q4 24
57.9%
8.1%
Q3 24
-127.8%
5.4%
Q2 24
44.2%
-10.7%
Net Margin
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
39.9%
19.4%
Q3 25
82.4%
14.3%
Q2 25
29.3%
-9.3%
Q1 25
39.5%
-21.7%
Q4 24
57.7%
6.1%
Q3 24
-127.9%
10.7%
Q2 24
44.1%
-13.1%
EPS (diluted)
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
$0.19
$0.31
Q3 25
$0.34
$0.11
Q2 25
$0.12
$-0.10
Q1 25
$0.16
$-0.17
Q4 24
$0.25
$0.05
Q3 24
$-0.69
$0.09
Q2 24
$0.23
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARI
ARI
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$139.8M
$91.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
Total Assets
$9.9B
$520.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARI
ARI
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$139.8M
$93.7M
Q3 25
$245.9M
$63.7M
Q2 25
$177.6M
$73.1M
Q1 25
$166.4M
$110.0M
Q4 24
$317.4M
$135.6M
Q3 24
$194.3M
$94.3M
Q2 24
$174.7M
$89.9M
Total Debt
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Stockholders' Equity
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
$1.9B
$300.1M
Q3 25
$1.9B
$255.1M
Q2 25
$1.8B
$233.2M
Q1 25
$1.9B
$242.9M
Q4 24
$1.9B
$262.9M
Q3 24
$1.9B
$278.5M
Q2 24
$2.0B
$263.5M
Total Assets
ARI
ARI
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$9.9B
$598.7M
Q3 25
$9.5B
$509.8M
Q2 25
$9.8B
$461.1M
Q1 25
$8.8B
$467.4M
Q4 24
$8.4B
$497.9M
Q3 24
$9.1B
$446.3M
Q2 24
$9.3B
$443.2M
Debt / Equity
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARI
ARI
ORGO
ORGO
Operating Cash FlowLast quarter
$142.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
4.88×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
$142.5M
$39.4M
Q3 25
$31.7M
$3.1M
Q2 25
$63.2M
$-32.9M
Q1 25
$39.3M
$-19.9M
Q4 24
$200.3M
$10.9M
Q3 24
$47.2M
$8.7M
Q2 24
$50.2M
$4.7M
Free Cash Flow
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
ARI
ARI
ORGO
ORGO
Q1 26
Q4 25
4.88×
0.90×
Q3 25
0.62×
0.14×
Q2 25
3.05×
Q1 25
1.51×
Q4 24
4.93×
1.43×
Q3 24
0.71×
Q2 24
1.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons